Boston biotech startup closes $4M Series B with plans for brain injury biomarker test

Imagine a device that could diagnose brain injury almost immediately after severe head trauma by measuring the proteins released after impact. BioDirection, a Boston-based startup, is building that tool, and funding from a $4 million Series B round is going to help.

Advertisement

BioDirection’s system, called Tbit, is portable and uses a nanotechnology sensor. The company is betting it will reduce the need for unnecessary CT scans and help patients with head injuries get the correct diagnosis and treatment faster.

This round brings the company’s total funds raised to $10 million, which BioDirection says it will use to speed up the final development stages of Tbit and begin the commercialization process. Provident Healthcare Capital led the round. 

More articles on health IT:

10 startups to know for 2016
Harvard startup Gain Life aims to put ‘lifestyle medicine’ on the map
Startup aims to give hospital patients VIP experience

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Health IT

Advertisement

Comments are closed.